Oral Answers to Questions

Ben Howlett Excerpts

Thursday 26th January 2017 Commons Chamber

[Mr David Davis]

That is all very well, but the complete premise of the question is wrong. That is not what the Health Secretary said; he was misreported and misinterpreted. What I will say to the hon. Lady is this: what we will be doing is, first, putting the clinical safety of the British people at the front of the priority list, and then looking after the interests of British industry, particularly biosystems and life sciences, in which we are a world leader now and will continue to be after we leave.

[Ben Howlett (Bath) (Con)]

As chair of the all-party group on rare, genetic and undiagnosed conditions, I know that the issue of clinical trials is a big one for patients, as they are concerned that exiting the EU will mean that nothing will replace those trials. Will my right hon. Friend assure the House and those patients that the trials will be replicated as soon as we leave the EU?

[Mr David Jones]

I can assure my hon. Friend that we are in extensive discussions with the biopharma industry on that particular issue, and those discussions will continue.